Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47,579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2017 Chinese expert consensus on the clinical application of serum marker for thyroid cancer.
Gao M, Ge M, Ji Q, Cheng R, Lu H, Guan H, Cui W, Gao L, Gao Z, Guo L, Guo Z, Huang T, Huang X, Lin Y, Liu Q, Ni X, Qin J, Ren L, Shan Z, Sun H, Wang X, Xu Z, Yu Y, Zhang B, Zhao D, Zheng Y, Zhu J, Zheng X, Chinese Association Of Thyroid Oncology Cato China Anti-Cancer Association. Gao M, et al. Among authors: huang t, huang x. Cancer Biol Med. 2018 Nov;15(4):468-477. doi: 10.20892/j.issn.2095-3941.2018.0084. Cancer Biol Med. 2018. PMID: 30766757 Free PMC article. No abstract available.
2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma.
Gao M, Ge M, Ji Q, Cheng R, Lu H, Guan H, Gao L, Guo Z, Huang T, Huang X, Li X, Lin Y, Liu Q, Ni X, Pan Y, Qin J, Shan Z, Sun H, Wang X, Xu Z, Yu Y, Zhao D, Zhang N, Zhang S, Zheng Y, Zhu J, Li D, Zheng X, Chinese Association Of Thyroid Oncology Cato Chinese Anti-Cancer Association. Gao M, et al. Among authors: huang t, huang x. Cancer Biol Med. 2017 Aug;14(3):203-211. doi: 10.20892/j.issn.2095-3941.2017.0051. Cancer Biol Med. 2017. PMID: 28948061 Free PMC article. No abstract available.
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y, Luo Y, Zhang Q, Huang X, Li Z, Shen L, Feng J, Sun Y, Yang K, Ge M, Zhu X, Wang L, Liu Y, He X, Bai C, Xue K, Zeng Y, Chang X, Chen W, Lin T. Guo Y, et al. Among authors: huang x. Eur J Cancer. 2021 Oct;156:35-45. doi: 10.1016/j.ejca.2021.06.039. Epub 2021 Aug 18. Eur J Cancer. 2021. PMID: 34418665 Free article. Clinical Trial.
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Shen L, et al. Among authors: huang x. J Immunother Cancer. 2020 Jun;8(1):e000437. doi: 10.1136/jitc-2019-000437. J Immunother Cancer. 2020. PMID: 32561638 Free PMC article. Clinical Trial.
47,579 results
You have reached the last available page of results. Please see the User Guide for more information.